Neurotech & BCI
PrivateA $850M valuation at inception for a read-only ultrasound BCI whose recording modality still needs a hole in the skull — Merge is a bet on Altman, OpenAI distribution, and a 3-to-5-year science miracle (through-skull fUS + sonogenetic gene delivery), not on a product; nothing to underwrite until it shows transcranial human signal that Forest Neurotech itself has not yet shown.
Research
The verdict
A $850M valuation at inception for a read-only ultrasound BCI whose recording modality still needs a hole in the skull — Merge is a bet on Altman, OpenAI distribution, and a 3-to-5-year science miracle (through-skull fUS + sonogenetic gene delivery), not on a product; nothing to underwrite until it shows transcranial human signal that Forest Neurotech itself has not yet shown.
Merge Labs is a pre-revenue, pre-clinical neurotechnology research lab building brain-computer interfaces (BCIs) that read and modulate brain activity without electrode implants, using ultrasound and engineered molecules instead of electrodes. It defines itself as a "research lab" with the mission of "bridging biological and artificial intelligence to maximize human ability, agency, and experience". There is no product, no clinical indication, no deployment timeline, and no revenue — neurofounders.co, reading Merge's own job postings, notes "the company has not outlined specific product targets, clinical indications, or deployment timelines" and shows "early emphasis on building internal capability around the core technical thesis before defining downstream applications or products".
The technical thesis (the whole company in one paragraph). Merge's stated belief is that "increasing bandwidth and brain coverage of BCIs by several orders of magnitude while making them much less invasive requires developing entirely new technologies that connect with neurons using molecules instead of electrodes [sonogenetics / acoustic reporter genes], and transmit and receive information using deep-reaching modalities like ultrasound". Two mechanisms underlie this (detailed in Lens 2/3):
Who the "customers" will be: undefined. The long-run framing is consumer-adjacent — Altman's pitch is a "think a thought, get a ChatGPT response" read-only, low-friction link to an AI agent (contrast Musk's "high-bandwidth symbiosis"). OpenAI's stated rationale is explicitly distribution-circular: "BCIs will create a natural, human-centered way for anyone to seamlessly interact with AI" — i.e., a new input layer for ChatGPT. There is no medical indication, no reimbursement path, and no SKU. n/a — private, not disclosed on every revenue line.
Contract / payment structure: none exists. Unlike an operating company, there is nothing to assess here — no recurring revenue, no take-or-pay, no concentration. The only "contract" of note is the OpenAI collaboration (scientific foundation models + frontier tools), terms undisclosed.
Leadership ambiguity (flagged, not resolved). Sources conflict on who actually runs Merge day-to-day. Several outlets call Alex Blania "CEO" of Merge Labs while simultaneously reporting he "will continue his role at Tools for Humanity" (Worldcoin), and Sumner Norman is described as CEO of Forest Neurotech. It is not clear from public sources whether Merge has a dedicated full-time CEO or is run by part-time founder-operators plus the Forest/Caltech scientific bench. I treat the executive-attention question as a live risk (Lens 9/13), not a settled fact.
There is no commercial-layer file for the bci beat (supply-chain.md missing), so this is web-derived. Map of the value chain Merge sits in:
Upstream — the enabling hardware & science:
Midstream — Merge Labs: integrates chip-ultrasound + decode-AI + (eventually) sonogenetic molecular reporters into a device/platform. No fab, no clinical sites of its own disclosed (Forest used UCLA Neuro-ICU and Cedars-Sinai).
Downstream — the buyer: undefined and unbuilt. Long-run intent is consumer/AI-interface (route to OpenAI/ChatGPT) rather than the medical-reimbursement channel that Neuralink/Synchron/Precision target. No distribution, no payer, no regulatory clearance.
Chokepoints / single-source dependencies: (1) Butterfly's ultrasound-on-chip is the named hardware chokepoint; (2) the skull is the physical chokepoint (see the grounding note — fUS recording can't cross it non-invasively today); (3) gene delivery is the chokepoint for the sonogenetic layer. All three are unresolved.
What is genuinely differentiated:
Bargaining power: as a pre-product lab, Merge has none over a future supply chain or future customers — it has it only over talent and capital (where the Altman halo gives it leverage). Butterfly/gene-delivery vendors would hold the leverage in any real build.
Why the moat may be thinner than it looks (carried into Lens 13): the defensible asset is science that lives substantially at Caltech and Forest, with several founders part-time (Blania/Herbig at Tools for Humanity, Norman at Forest, Shapiro at Caltech). The IP is licensable/replicable by a well-funded rival (and the field is small — every serious fUS-BCI person knows every other one). The "moat" is money + Altman + OpenAI, which is formidable for fundraising and recruiting but does not protect a specific technical claim. Durability is unproven on every axis except capital access.
n/a — private, pre-revenue. There are no product segments, no geographic revenue split, no EBITDA — segments.csv is header-only and there is nothing to populate it with. The only meaningful "segmentation" is programmatic: a read program (fUSI decode), a write program (FUS neuromodulation), and a molecular program (sonogenetic reporters) — none of which is a revenue line. Recorded here as required; quantification is n/a — not disclosed.
All figures ``, unaudited.
| Round | Date | Amount | Lead | Other named investors | Valuation | Source |
|---|---|---|---|---|---|---|
| Seed | Jan 2026 (stealth exit 15 Jan) | ~$250–252M | OpenAI ("largest single check") | Bain Capital, Interface Fund, Fifty Years, Gabe Newell | ~$850M post |
That is the entire capital history — Merge is one round old.
The number that matters and why it's the story: ~$850M valuation at inception, pre-product, pre-clinical, pre-revenue. neurofounders.co: this "resembles late-stage financing in neurotechnology, despite Merge being newly formed," and "commits comparable-scale capital to a non-implant, experimental ultrasound-based approach at a point where the modality itself remains the primary uncertainty". For calibration: Neuralink took ~9 years and 11 implanted patients to reach ~$9B; Synchron is at ~$1B with 10 implants and an FDA IDE; Precision is ~$500M with an actual FDA 510(k) clearance. Merge is at $850M with zero patients, zero clearances, and an unproven recording modality — it is priced off founder + OpenAI optionality, not de-risking.
Burn signal: a research lab hiring "senior technical and research roles" to build ultrasound + AI-decode + (eventually) gene-delivery capability, in the Bay Area, burns on the order of **$30–60M/yr **. On ~$250M that is ~4–7 years of runway if it stays a lab and doesn't fund expensive human gene-therapy trials — generous by frontier standards, and the reason there's no urgency to define a product. The flip side: the first serious clinical/gene-delivery program would compress that fast.
No guidance, no print, no balance sheet to flag. guidance.csv / financials.csv are header-only by necessity. There is nothing to reconcile because nothing has been reported.
No earnings calls exist; the "sentiment" tape is announcements + founder interviews.
Syndicate quality. Lead is OpenAI (strategic, not a crossover fund — and the source of the conflict overhang, Lens 9/10), plus Bain Capital (real institutional money), Interface Fund, Fifty Years (deep-tech/longevity), and Gabe Newell (Valve founder, a known neurotech enthusiast/Starfish-adjacent). Tell: this is a strategic + deep-tech-VC + celebrity-angel syndicate, not a Fidelity / T. Rowe / Coatue crossover cap table — so the classic IPO-proximity signal is absent, exactly as you'd expect one round in. The Altman/OpenAI anchor substitutes brand for crossover validation.
Secondary marks: none disclosed. Forge / PitchBook / Tracxn list Merge but carry only the $850M primary mark (Jan 2026) — there is no secondary trading or markup/markdown to cite. n/a — not disclosed.
Mechanism / valuation comps — the BCI cohort (private marks, ``; never fabricated — n/a where unsourced; cross-checked against this shelf's peer dossiers):
| Company | Approach | Bandwidth / status | Latest valuation / raise | Source |
|---|---|---|---|---|
| Merge Labs | fUS read + FUS write + sonogenetic (non-electrode), aspires non-invasive | Pre-clinical, 0 patients, modality unproven through skull | ~$850M (Seed $252M, Jan 2026, OpenAI-led) | |
| Neuralink | Intracortical threads + robot (invasive) | 1,024 ch; ~21 implanted | ~$9–9.7B (Series E $650M, Jun 2025) | |
| Synchron | Endovascular stentrode (no craniotomy) | 16 ch, low-bandwidth; 10 implanted; FDA IDE; Apple BCI-HID | ~$1B (Series D $200M, Nov 2025, Double Point) | |
| Precision Neuroscience | Cortical-surface film (non-penetrating) | 1,024 ch / 1 cm²; FDA 510(k)-cleared (30-day) | ~$500M (Series C $102M, Dec 2024); ~$180M total | |
| Paradromics | High-density intracortical | First-in-human Jun 2026 (EFS) | ~$88.7M–$500M (disputed) | |
| Blackrock Neurotech | Utah array (incumbent) | Longest human track record | ~$350M | |
| Kernel | Non-invasive TD-fNIRS (consumer/wellness) | Capital-starved; pivoted to BrainAge | ~$158M total, no priced round since 2020 | [companies/kernel; private-watch.json] |
The comp read (this is the whole valuation argument): Merge at $850M sits above Precision ($500M, FDA-cleared, shipping) and near Synchron's earlier rounds ($1B, 10 implants, FDA IDE) — with none of their clinical de-risking. On evidence-per-dollar it is the most expensive BCI in the cohort. The bull retort (Lens 12) is that it is the only one with a credible non-invasive-coverage path and OpenAI distribution; the bear retort (Lens 13) is that Kernel is the cautionary comp — a well-funded non-invasive-BCI dream that ran out of road when the signal proved too thin to build a business on. Merge is being priced like the bull case is already true.
No public stock, so "catalysts" are mark-resetting events:
Founders (the asset and the risk):
Skin in the game / tenure: founders are brand-new to this company and several are explicitly part-time (Blania/Herbig at TfH, Norman at Forest, Shapiro at Caltech). Altman holds no equity (per reports) — which removes one conflict but also dilutes "skin in the game." The executive-attention question is the central management risk: who wakes up every day owning Merge's P&L of progress? Public sources do not answer this.
Capital-allocation history: too new to judge at Merge. The adjacent record (Worldcoin) shows founders who raise big and spend on global hardware scale-up aggressively — capital-intensive, regulation-courting. No value-destruction at Merge yet because nothing has been allocated beyond hiring.
Founder vs. professional manager: founder/visionary archetype, heavily — mission-first, narrative-first, science-bench-deep, operationally part-time at the top. Implication: fundraising and recruiting will be elite; focus, regulatory discipline, and accountability are the open questions.
Accounting/financial forensics: n/a — no financials exist. There is no income statement, balance sheet, or cash-flow statement to interrogate — no revenue recognition, receivables, SBC, or goodwill to flag. The honest forensic statement for a one-round-old private lab is: there is nothing to audit, and that opacity is itself the caveat — every figure in this dossier is company-stated or press-reported, none independently verified.
Regulatory findings (required sub-section). Read companies/merge-labs/regulatory/regulatory-findings.md (written 2026-06-29 by fetch-regulatory-findings.ts):
n/a — no 10-K exists."Merge Labs" (FTC OR DOJ OR FDA OR...) enforcement): no enforcement action against Merge Labs itself found as of 2026-06-29 — it is too new and pre-clinical to have a regulatory record ``.There is no EPS to project — pre-revenue, pre-product. No forecast.ts EPS line is logged (correct per --watchlist rules; there is nothing committable yet). The relevant projection is path-to-tradeable:
private-watch.json readiness scale (1=early/seed … 5=S-1 filed), Merge is a 1/5.research/private-watch.json under beat: bci with stage: seed, ipo_readiness: 1, lead OpenAI (+ Bain, Fifty Years, Gabe Newell), catalyst "$850M-at-inception ultrasound/sonogenetic non-invasive BCI; modality unproven through skull; OpenAI conflict overhang", and dossier set to this file. (Per wave boundaries I do NOT edit that file here — flagged for Connor's /thesis/coverage pass.)The forecast that is worth tracking (binary, not EPS — log later if conviction forms): "Merge Labs publicly demonstrates human brain-activity recording (fUS or sonogenetic) without skull removal / cranial window by YE2028." My prior : low — ~20–30% given that Forest's own science still needs a window. That single binary, not a revenue number, is what should be calibrated for this name.
Bull case. Merge is the only BCI attacking the prize that actually matters for a consumer AI-interface era: whole-brain, deep, non-electrode coverage at scale, with a path to non-invasive. Electrode arrays (Neuralink/Precision) sample a postage-stamp of cortex and require neurosurgery — a ceiling on TAM. fUS already has ~100 µm resolution, deep penetration, and peer-reviewed human results; pair that with OpenAI's decode models and Butterfly's ultrasound-on-chip miniaturization, and you have a credible 10-year route to a wearable, no-surgery brain input for ChatGPT — a market measured in hundreds of millions of consumers, not thousands of paralysis patients. The founders combine the best fUS-BCI scientists alive (Norman, Aflalo, Shapiro) with operators who actually scaled global consumer hardware (Blania/Herbig). With Altman + OpenAI + $250M, it has the capital, brand, and distribution moat to out-recruit and out-fund every rival. At $850M it is "cheap" relative to a Neuralink at ~$9B if the non-invasive thesis lands — because non-invasive is worth an order of magnitude more TAM than invasive. Contrarian view the market is refusing to see (bull side): the BCI race is being scored on bandwidth and implants (Neuralink's frame), but the consumer-AI era will be won on zero-surgery + good-enough read-only bandwidth — and Merge is the only well-capitalized team building exactly that.
Bear case (the stronger case, given the price). Three things could permanently impair this:
Pre-mortem (18 months out, thesis broke): it's mid-2027. Merge has published nothing showing through-skull human recording; the work that exists still needs a window. The House Oversight / SEC scrutiny of Altman's self-dealing has made OpenAI quietly distance itself, removing the distribution-and-capital halo. A Worldcoin-style biometric backlash has attached to the founders' "scan-you-for-AI" brand, poisoning the consumer narrative. Meanwhile Synchron/Precision keep shipping real clinical milestones. The $850M mark looks like a founder-premium top-tick, and the next round is a flat-or-down strategic check from the Altman orbit because no crossover will touch it. What happened: the market paid for the story before the physics paid out.
Are multiples too high? There are no multiples (no revenue). On evidence-per-dollar, yes — it is the most expensive, least de-risked name in the BCI cohort. The valuation is pure option value on a science breakthrough + an Altman/OpenAI exit.
Dismantling the bull case:
companies/kernel]. Merge is a better-funded, better-branded re-run of the same bet, and the physics hasn't changed. Separately, Synchron quietly de-risks the "minimally-invasive + good-enough-bandwidth + Apple-distribution" lane that could satisfy the consumer-input use case years before Merge's through-skull dream.Cheapest large-cap medtech (fwd P/E ~13x, ~half of BSX/SYK) finally inflecting — PFA + Hugo + an Elliott-forced cost/portfolio reset put a credible re-rating in play, but the whole thesis rests on one unproven number: does organic growth hold above 5%?
A non-invasive, AR-first AAC headset with a real FDA-Breakthrough wedge and two distribution partners — but at a ~$25–46M valuation after 12 years and ~$25–32M raised, it is a mission-driven research-tools / assistive-device niche player, not a venture-scale BCI bet; the asymmetry is acquisition-by-a-giant, not an IPO.
The safest, most surgically scalable path into the brain and the only BCI Apple made a native input — but it bet the company on "good enough" 16-electrode bandwidth, and its own third-gen "whole-brain" pivot is a confession that the moat it is famous for may be the ceiling it has to escape.